Methylphenidate News and Research

RSS

Highland subsidiary begins enrolment in Phase III study of HLD-200 in pediatric ADHD patients

Highland Therapeutics Inc., an emerging pharmaceutical company, today announced that its wholly owned subsidiary has begun enrolment in a Phase III study of HLD-200, the Company's novel formulation of methylphenidate, in pediatric patients with Attention-Deficit Hyperactivity Disorder ("ADHD").

28 Apr 2014

Methylphenidate may prevent depletion of self-control

Methylphenidate, also known as Ritalin, may prevent the depletion of self-control, according to research published in Psychological Science, a journal of the Association for Psychological Science.

25 Apr 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

K-PAX Pharmaceuticals works with Stanford University to identify effective treatment for chronic fatigue

K-PAX Pharmaceuticals is working with Stanford University and several other leading research institutions to perform a Phase II double-blind, placebo-controlled trial to evaluate the safety and efficacy of a currently available FDA-approved medication concurrently administered with a novel mitochondrial support product in order to identify a safe and effective treatment for the chronic fatigue and decreased alertness (i.e. brain fog) that commonly afflicts people with CFS.

26 Feb 2014

Mallinckrodt’s net sales increase $540.2M to 7.2% in first quarter 2014

Mallinckrodt plc, a global specialty pharmaceutical and medical imaging business, today reported results for the first quarter of fiscal 2014, which ended December 27, 2013. The company also announced revised guidance for fiscal 2014.

6 Feb 2014

Study supports use of two drugs for treating children with aggression and disruptive behavior

Prescribing both a stimulant and an antipsychotic drug to children with physical aggression and attention-deficit/hyperactivity disorder, along with teaching parents to use behavior management techniques, reduces aggressive and serious behavioral problems in the children, according to a study conducted by researchers at The Ohio State University Wexner Medical Center.

22 Dec 2013

Chemists able to trace narcotics substances, prescription drugs in Swedish wastewater

Chemists at Ume- University in Sweden have been able to trace narcotics substances and prescription drugs in measurements of wastewater from 33 Swedish sewage treatment plants. Cocaine, amphetamine, and methamphetamine, in measurable concentrations, were found in a total of half of the locations.

17 Dec 2013

Studies prove that students use prescription drugs to enhance cognitive performance

American and European studies prove that students use prescription medication or drugs to enhance their cognitive performance. Researchers from the universities of Zurich and Basel examined whether Swiss students have also experimented with neuroenhancement and which substances they take by conducting a survey of 6,725 students with an average age of 23 at the two universities and ETH Zurich.

16 Nov 2013

High doses of ADHD drugs may be effective for people with amphetamine dependency

People with ADHD and dependency rarely respond as they should to ADHD drugs. A randomised study from Karolinska Institutet in Sweden now shows that it is possible to obtain the desired efficacy by administering the drug in higher doses.

15 Oct 2013

Study finds increase in use of stimulant medications to treat children and teens with ADHD

Use of stimulant medications to treat Attention-Deficit/Hyperactivity Disorder in children and adolescents has increased significantly over the past several years.

11 Sep 2013

Single dose of methylphenidate can reduce risk of falls among elderly adults

Ben-Gurion University of the Negev researchers have discovered that a single dose of methylphenidate, used to treat Attention Deficit Hyperactivity Disorder and narcolepsy, helps to improve balance control during walking, hence reducing the risk of falls among elderly adults.

18 Jul 2013

Ritalin helps improve brain function in cocaine addiction

A single dose of a commonly-prescribed attention deficit hyperactivity disorder drug helps improve brain function in cocaine addiction, according to an imaging study conducted by researchers from the Icahn School of Medicine at Mount Sinai.

28 Jun 2013

Highland Therapeutics subsidiary reports positive HLD-200 Phase-1 results in ADHD patients

Highland Therapeutics, Inc., a specialty pharmaceutical company based in the MaRS Discovery District in Toronto, today announced that its wholly owned subsidiary has generated positive Phase-1 results for HLD-200 - a novel formulation of methylphenidate being developed to treat the symptoms associated with Attention-Deficit/Hyperactivity Disorder.

25 Jun 2013

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire plc, the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in San Francisco, May 18-22.

20 May 2013

Methylphenidate normalizes activation of several brain areas in children with ADHD

The stimulant drug methylphenidate "normalizes" activation of several brain areas in young patients with attention-deficit/hyperactivity disorder (ADHD), according to a review published in the May Harvard Review of Psychiatry. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

10 May 2013

Over 90% of medical specialists do not follow ADHD guidelines

A recent study by pediatricians from the Cohen Children's Medical Center of New York examined to what extent pediatric physicians adhere to American Academy of Pediatrics (AAP) clinical guidelines regarding pharmacotherapy in treating young patients with Attention Deficit Hyperactivity Disorder (ADHD).

6 May 2013

Covidien net sales increase 5% to $3.10 billion in second quarter 2013

Covidien plc today reported results for the second quarter of fiscal 2013 (January - March 2013). Second-quarter net sales of $3.10 billion increased 5% from the $2.95 billion reported in the second quarter a year ago. Foreign exchange rate movement lowered the quarterly sales growth rate by two percentage points.

26 Apr 2013

Study establishes possible link between high-fat diets and ADHD, learning disabilities

A University of Illinois study has established a possible link between high-fat diets and such childhood brain-based conditions as attention deficit hyperactivity disorder (ADHD) and memory-dependent learning disabilities.

19 Feb 2013

New DNA chip could improve diagnosis and therapeutics of ADHD

Attention Deficit Hyperactivity Disorder (ADHD) is the most common childhood neuropsychiatric disorder. Yet there is currently no tool that will confirm the diagnosis of ADHD. In her thesis entitled "Development of a genotyping system to be applied in Attention Deficit Hyperactivity Disorder and its Pharmacogenetics".

22 Jan 2013

Pfizer’s Quillivant XR now available in the U.S. for treatment of ADHD

Pfizer Inc. today announced that Quillivant XR (methylphenidate hydrochloride) CII for extended-release oral suspension is now available in the U.S. for the treatment of attention deficit hyperactivity disorder (ADHD).

16 Jan 2013